Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis

Acta Dermato-Venereologica

Volumn 89, Issue 3, 2009, Pages 332-334

  Kluger, Nicolas ^a   Girard, Céline ^a   Guillot, Bernard ^a   Bessis, Didier ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE; INFLIXIMAB; METHOTREXATE; PSORALEN; RETINOID; SALAZOSULFAPYRIDINE;

ACUTE HEPATITIS; ADULT; ANAMNESIS; ARTHRALGIA; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; PSORIASIS; TREATMENT DURATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HEPATITIS, TOXIC; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 66749098960     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0619     Document Type: Letter

References (9)

1. United States Food and Drug Administration. Safety alerts for drugs, biologies medical devices, and dietary supplements. Remicade (infliximab). Washington DC: FDA, 2004. Available from: URL: http://www.fda.gov/medwatch/ SAFETY/2004/safety04.htm#Remicade2 [accessed Sept 2008].
2. Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26: 578-581. (Pubitemid 46359303)
3. United States Food and Drug Administration Briefing Document. Arthritis Advisory Committee. Available from: URL: http://www.fda.gov/ohrms/dockets/ac/03/ transcripts/3930T1.htm [accessed Sep 2008].
4. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003; 30: 1624-1625. (Pubitemid 36835467)
5. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-1082. (Pubitemid 37323572)
6. Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007; 187: 524-526.
7. Wahie S, Alexandroff A, Reynolds NJ. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 2006; 31: 460-461.
8. Thiéfin G, Morelet A, Heurgué A, Diebold MD, Eschard JP. Infliximab-induced hepatitis: Absence of cross-toxicity with etanercept. Joint Bone Spine 2008; 75: 737-739.
9. García Aparicio AM, Rey JR, Sanz AH, Alvarez JS. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 2007; 26: 811-813. (Pubitemid 46554102)